• Explore /
  • Poster
  • / A phase 2 study of durvalumab plus DOS (docetaxel, oxaliplatin, S-1) neoadjuvant chemotherapy followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in patients with resectable locally advanced gastric cancer: An interim efficacy report.

A phase 2 study of durvalumab plus DOS (docetaxel, oxaliplatin, S-1) neoadjuvant chemotherapy followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in patients with resectable locally advanced gastric cancer: An interim efficacy report.

Abstract Poster

Authors

Hyung-Don Kim

Hyung-Don Kim

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea;

Hyung-Don Kim , Min-Hee Ryu , Young Soo Park , Jong Seok Lee , Yoon-Koo Kang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

04221555

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 408)

DOI

10.1200/JCO.2023.41.4_suppl.408

Abstract #

408

Poster Bd #

H11

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).

Randomized phase II study comparing neoadjuvant FLOT versus DOS for patients with type 4 or large type 3 gastric cancer (JCOG2204).

First Author: Izuma Nakayama

First Author: Jaewon Hyung

First Author: David Tougeron

First Author: Ho Yeong Lim